Trial Profile
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Diffuse large B cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 07 Jul 2021 Status changed from active, no longer recruiting to completed.
- 02 Jun 2021 Planned End Date changed from 1 Mar 2022 to 1 Jun 2021.
- 03 Apr 2020 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.